Categories with relatively robust evidence include curcuminoids (phospholipid curcumin meriva), which have shown NASH resolution in biopsy-proven trials; alkaloids (berberine), which have improved liver enzymes in small-scale RCTs; and phenolic acids (ellagic acid), which have ameliorated insulin resistance in NAFLD patients. This evidence concerns the gene INS and metabolic dysfunction-associated steatohepatitis.